Skinbiotherapeutics Share Discussion Threads

[rayrac] 09/9/2020 10:28

Is there a product off the ‘production line’ yet? And where are the up-front fees to Opti?!

[gary hindsight] 09/9/2020 10:15

You say sure they will look at it. Don't you think they did that before investing 5m in the production line? You think they did that without having a clue of the benefits over matrixyl? Let's spend 5m and see what happens ?

[rayrac] 09/9/2020 10:06

Croda? They are sure to look at it. But it amounts to the same thing...got to be proven.

[gary hindsight] 09/9/2020 09:59

Ok maybe we should make sure we are talking about the same thing first. If you are talking about the psoriasis treatment I agree with you it's not proven yet. If you are talking about the sbtx for croda I don't agree with youCan we agree on that ?

[rayrac] 09/9/2020 09:40

Btw Gary, it’s unproven.

[rayrac] 09/9/2020 09:38

I’m just saying the tech is unproven Trump...hence the trials

Stop trying to suggest otherwise!

[gary hindsight] 09/9/2020 09:31

RayYou say that science yet to be proved yet it's been confirmed that sederma saw the same results from their newly commissioned production line that sbtx saw in development. Doesn't suggest the science was a fluke and also suggests croda saw the commercial benefit of sbtx when signing the deal in the first place. Which bit of that says it's unproven

[trumpingtonsmythe] 09/9/2020 09:06

Thanks Ray, yes when the product is developed the price will rise. Now how do you develop things, let's get a time served expert and go to trials. Are you suggesting you know the trials have failed, that would be insider info?

[atlantic57] 09/9/2020 09:03

The Advfn bb are very amusing.

When a share is rising ,the board is full of posters telling you how high it will go.

When it starts falling Suddenly the doom and gloom posters emerge.

As far as I am aware there have been no changes in the company position.

However there have no news announcements and of course market conditions have changed.

[rayrac] 09/9/2020 08:17

TrumpingtonSmythe8 Sep '20 - 07:41 - 6560 of 6569
0 3 0
Or

‘CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes.’

Is adding to the area where strength is needed, the tech is fine it’s the development knowledge that’s needed?

The tech is unproven, otherwise the share price would be far higher!?

Pied piper at play

[slartybartfaster] 08/9/2020 18:20

Don't worry, almost 3 years even if the employ you to do some PR. Clown.

[lovewinshatelosses] 08/9/2020 11:19

While it would have been nice to see a sizeable spike in the share price after that RNS, it does have the feel of a positive, additional building block sliding into place IMO. That said, we will be in a position to judge his success, or otherwise, within six months or so.

[trumpingtonsmythe] 08/9/2020 09:09

Accelerated product development is not negative! Avoiding product development pitfalls is not negative! Having contacts across the product development landscape is not negative! Having an open short can be painful.

[gary hindsight] 08/9/2020 08:56

Seems a good appointment to me. I would think given his background his first task will be to get the clinical studies for the psoriasis underway. As ceo at his last job this would seem to have be its main purpose.

[m4rtinu] 08/9/2020 08:40

Obv a cost in short term but would appear a price worth paying. Within reason.

[aquaesulis01] 08/9/2020 08:40

What a short sighted comment that was best. If you do not invest for the future as a company, at the right time, you fail to grow. Great relevant experience and NHS network contacts which will help promote the positive aspects of the companies products going forward.

[best1467] 08/9/2020 07:54

Will increase cash burn only negative

[parob] 08/9/2020 07:44

Dr Jonathan Sheffield has been Chief Executive Officer of the National Institute for Health Research, Clinical Research Network since 2010. The Clinical Research Network delivers Clinical research studies throughout the NHS in England covering primary, secondary and tertiary care. The University of Leeds and Guy's and St Thomas' NHS Foundation Trust host the Network's Coordinating Centre from offices based in Leeds, London, Liverpool and Newcastle. In 2016-17 the Network recruited over 666,000 patients into over 4000 studies across the NHS. Jonathan qualified as a doctor in 1981 and subsequently trained as a Histopathologist. In 1993 he was appointed as a Consultant Histopathologist at Yeovil district General Hospital. Subsequently Jonathan has held multiple senior medical management posts in the NHS at local, regional and a national level.Jonathan is highly regarded for his knowledge and expertise and is often called upon to speak at national events and international industry meetings. In his capacity as an NIHR spokesperson, he provides comment on research delivery throughout the NHS infrastructure. His long and detailed experience in the NHS allows him to balance contentious clinical priority issues with the need to advance medical knowledge through research.A passionate advocate for clinical research, Jonathan's ambition is to focus not only on traditional pharma and medical technology research but how digital tools can accelerate delivery of life-changing treatments whilst improving engagement with patients, researchers, Life Science industry and the wider NHS.hTTps://business.leeds.ac.uk/divisions-management/dir-record/academic-industry-profiles/998/dr-jonathan-sheffield

[trumpingtonsmythe] 08/9/2020 07:41

Or'CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes.'Is adding to the area where strength is needed, the tech is fine it's the development knowledge that's needed?

[rayrac] 08/9/2020 07:38

Dr Jonathan Sheffield, Senior Medical Advisor at SkinBioTherapeutics, said:

"Throughout my career I have been passionate about innovative, ground-breaking science, and how medical knowledge can be advanced through clinical research to improve lives. SkinBioTherapeutics' technology is one that is grounded in compelling science and has the potential to make a material difference for patients in several areas through its multiple programmes. I look forward to getting to know the team and the technology over the coming months."

So he knows nothing about the technology, but, likes the idea?!

Woooooow the pied piper at it again?

[deeppockets] 08/9/2020 07:32

He wouldn't join just any old start up and would want to be associated with a genuine up and coming technology.

[m4rtinu] 08/9/2020 07:30

Excellent appt. Great wealth of medical knowledge and presumably contacts too.

[parob] 08/9/2020 07:26

Great addition to the team.Stuart Ashman, CEO of SkinBioTherapeutics, said:"Jonathan will bring to SkinBioTherapeutics broad clinical knowledge accumulated over his career. Having served as CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes."Dr Jonathan Sheffield, Senior Medical Advisor at SkinBioTherapeutics, said:"Throughout my career I have been passionate about innovative, ground-breaking science, and how medical knowledge can be advanced through clinical research to improve lives. SkinBioTherapeutics' technology is one that is grounded in compelling science and has the potential to make a material difference for patients in several areas through its multiple programmes. I look forward to getting to know the team and the technology over the coming months."

[zedder] 03/9/2020 09:09

The 35k was mine. I sold 34.5k on 11th August at 24.72p and in the meantime had a 20% ride on AAU. Back with a few more shares but have taken out £1500 to pay for a couple of things around the house.